Back to search

Peptide record

TPDB41433

C7A-D21K Anticancer standard

27 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41433

Peptide_Name

C7A-D21K

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 27-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KILRGVAKKIMRTFLRRISKKILTGKK-NH2

FASTA

>TPDB41433|Anticancer|length=27
KILRGVAKKIMRTFLRRISKKILTGKK-NH2

Formula C145H268N46O31S1

Absent Amino Acids NDCEQHPWY

Common Amino Acids K

Mass 3184.07

PI 12.89

Basic Residues 11

Acidic Residues 0

Hydrophobic Residues 11

Net Charge +11

Boman Index 6.22

Hydrophobicity -0.304

Aliphatic Index 115.56

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 3

number

Amino Acid Distribution

A: 1 R: 4 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 4 L: 3 K: 7 M: 1 F: 1 P: 0 S: 1 T: 2 W: 0 Y: 0 V: 1

Length

Formula

C145H268N46O31S1

Mass

3184.07

12.89

Net Charge

+11

Boman Index

6.22

Hydrophobicity

-0.304

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial Anticancer Antitumor

Origin

Synthetic peptide NK-2 variants NK-2 peptide based derivatives

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =8.4 ± 0.2 µM

Detail Source Activity Anticancer

Activity Measurement 8.4

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =12.3 ± 2.0 µM

Detail Source Activity Anticancer

Activity Measurement 12.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 2-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =8.3 ± 0.5 µM

Detail Source Activity Anticancer

Activity Measurement 8.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 =12.3 ± 1.0 µM

Detail Source Activity Anticancer

Activity Measurement 12.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 8.4±0.2 µM

Detail Source Activity Anticancer

Activity Measurement 8.4

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 30-Min

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 12.3±2.0 µM

Detail Source Activity Anticancer

Activity Measurement 12.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 2-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 8.3±0.5 µM

Detail Source Activity Anticancer

Activity Measurement 8.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 4-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 12.3±1.0 µM

Detail Source Activity Anticancer

Activity Measurement 12.3

Target

Cancer Type Skin Cancer

Cell Line E42/02

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 9 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability =50% at 12.5µM approx.

Detail Source Activity Anticancer

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 10 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 11 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 12 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >50% at 25µM approx

Detail Source Activity Anticancer

Activity Measurement >50 % at 25µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 13 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability =50% at 12.5µM approx.

Detail Source Activity Anticancer

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 1-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 14 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >40% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >40 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 15 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >55% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >55 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC18

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 16 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >55% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >55 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC24

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 17 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >80% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >80 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC40

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 18 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >60% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >60 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC60

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 19 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >65% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >65 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC113

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 20 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >80% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >80 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC32

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014

Evidence 21 Activity

Activity

Activity Endpoint Cell viability

Activity Raw

Cell viability >65% at 12.5µM approx

Detail Source Activity Anticancer

Activity Measurement >65 % at 12.5µM approx

Target

Cancer Type Colorectal Cancer

Cell Line HROC107

Tissue Affected Colon

Assay & Model

Assay Cell Viability assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2014